Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Antihistamine Drugs Industry Report 2025-2030: A $381
The Antihistamine Drugs Market is projected to grow from USD 279.74 million in 2024 to USD 381.39 million by 2030, driven by rising allergies, a growing geriatric population, and innovations in drug formulation. Key players include Johnson & Johnson, Sanofi, Pfizer, and Bayer. Challenges include market saturation, side effects, and stringent regulations.
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA®
The Phase 3 ASTRO study demonstrated significant clinical remission at Week 12 with TREMFYA®, meeting all secondary endpoints. Safety data aligned with QUASAR findings, and results are planned for presentation at medical meetings.
Related Clinical Trials:
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen
Johnson & Johnson submits sBLA to FDA for subcutaneous TREMFYA® induction regimen in UC, supported by Phase 3 ASTRO study achieving clinical remission at Week 12 and meeting all secondary endpoints.
Related Clinical Trials:
Phase 3 win for Protagonist Therapeutics with oral plaque psoriasis drug
ICONIC-LEAD study showed icotrokinra, a peptide drug blocking IL-23 receptor, induced significant psoriatic plaque clearance. Developed with Johnson & Johnson, Protagonist earned $115 million for phase 3 success, totaling $165 million in milestone payments. 65% of patients achieved clear skin (IGA 0 or 1) at week 16, and 50% achieved PASI90. Efficacy improved to 74% clear skin and 65% PASI90 by week 24, with no increased adverse events. Icotrokinra aims to match injectable systemic drug efficacy via oral administration.
Global Clinical Trials Connect Conference 2025: Collaboration, Innovation and Enhancing
Conference on global health and clinical trials addresses bioethics, regulations, patient recruitment, site selection, real-world data, data integration, outsourcing, vendor management, quality in trial conduct, risk-based monitoring, clinical auditing, financial planning, and innovative technologies. Focuses on networking, case studies, presentations, and round tables.
Global Clinical Trials Connect Conference 2025:
The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, real-world data, and risk-based monitoring, among others. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study opportunities.
Global Clinical Trials Connect Conference 2025
The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, data integration, outsourcing, and risk-based monitoring. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study presentations.
Methods for Identifying Ligand Binding Sites in Drug Discovery
The article introduces Daniel Beck and Karson Putt as authors, detailing their extensive backgrounds in medicinal chemistry and drug discovery, respectively. It also mentions reviewers Pablo Martín-Gago and Ravi Kurumbail, highlighting their significant contributions to the field, particularly in hit discovery and structural biology.
Top 10 pharmaceutical companies in the world
Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.
© Copyright 2024. All Rights Reserved by MedPath